Design Therapeutics Inc Cash Flow Conversion Efficiency
Design Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Design Therapeutics Inc (DSGN) has a cash flow conversion efficiency ratio of -0.056x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-11.16 Million) by net assets ($199.72 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Design Therapeutics Inc (2019–2024)
Cash flow conversion efficiency of Design Therapeutics Inc from 2019 to 2024. This chart illustrates how Design Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Design Therapeutics Inc stock price today for real-time trading data and today's change.
Design Therapeutics Inc Cash Flow Conversion Ratio Explained
Design Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Design Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Design Therapeutics Inc ranked by their cash flow conversion efficiency. Also see Design Therapeutics Inc market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Better Home & Finance Holding Company
NYSE:BETR
|
-0.797x |
|
Bénéteau S.A.
PA:BEN
|
-0.032x |
|
ShenZhen Zero-Seven Co Ltd
SHE:000007
|
0.554x |
|
Nantong JiangTian Chemical Co. Ltd.
SHE:300927
|
-0.003x |
|
Daewoong
KO:003090
|
0.036x |
|
Heren Health Co Ltd
SHE:300550
|
0.007x |
|
Jiangsu Baoli Asphalt
SHE:300135
|
-0.022x |
|
Jiangsu Huachen Transformer
SHG:603097
|
0.000x |
Annual Cash Flow Conversion Efficiency for Design Therapeutics Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Design Therapeutics Inc from 2019 to 2024. Review DSGN free cash flow debt coverage to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $242.10 Million | $-43.10 Million | -0.178x | +15.57% |
| 2023-12-31 | $277.69 Million | $-58.56 Million | -0.211x | -34.51% |
| 2022-12-31 | $327.31 Million | $-51.32 Million | -0.157x | -103.94% |
| 2021-12-31 | $382.13 Million | $-29.38 Million | -0.077x | -110.03% |
| 2020-12-31 | $-11.31 Million | $-8.67 Million | 0.766x | +1907.43% |
| 2019-12-31 | $-3.64 Million | $-139.00K | 0.038x | -- |
About Design Therapeutics Inc
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potenti… Read more